Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Biopharma Launches Trial Testing Nitric Oxide as COVID-19 Treatment

Streetwise Reports, Streetwise Reports
0 Comments| June 18, 2020

{{labelSign}}  Favorites

The design, timeline and takeaways of Beyond Air's study are presented in a ROTH Capital Partners report.

Click to enlarge

In a June 16 research note, ROTH Capital Partners analyst Scott Henry reported that Beyond Air Inc. (XAIR:NASDAQ) enrolled the first patient in its U.S. clinical trial that will test nitric oxide as a COVID-19 treatment. Data are expected in August.

"Nitric oxide has shown potential against viruses through blocking both RNA synthesis and viral replication. Data include in vitro analysis of SARS coronavirus and four patients with coronavirus," Henry indicated.

The analyst described the New York-based company's open-label study that is to be conducted at two sites. It will involve 20 patients who are hospitalized with COVID-19. To be randomized on a 1:1 basis, patients will receive standard supportive therapy alone or standard supportive therapy plus intermittent treatments of 80 parts per million (80 ppm) of nitric oxide over 40 minutes four times per day. Patients will be treated and evaluated for about seven days and then followed up at 30 days.

The trial's primary endpoint is time to clinical deterioration as determined by the need for noninvasive ventilation or oxygen via high flow nasal cannula or intubation. Other study endpoints will include viral load, need for additional oxygen, length of hospital stay, mortality and safety.

Henry highlighted that safety is the main focus of the U.S. study, as the maximum nitric oxide dose to be used in it is 80 ppm, which is "underdosed as antiviral therapy." The Canadian trial to follow, however, will concentrate on efficacy as it will test nitric oxide doses up to 150 ppm. Data from the Canadian trial are expected sometime in Q4/20.

ROTH has a Buy rating and an $11 per share target price on Beyond Air, the current share price of which is about $6.98. "We believe that the nitric oxide platform for Beyond Air is undervalued," commented Henry.

1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Disclosures from ROTH Capital Partners,Beyond Air, Flash Note, June 16, 2020

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Within the last twelve months, ROTH has received compensation for investment banking services from Beyond Air.

ROTH and/or its employees, officers, directors and owners own options, rights or warrants to purchase shares of Beyond Air stock.

Within the last twelve months, ROTH has managed or co-managed a public offering for Beyond Air.

ROTH Capital Partners, LLC expects to receive or intends to seek compensation for investment banking or other business relationships with the covered companies mentioned in this report in the next three months.


{{labelSign}}  Favorites


No comments yet. Be first to comment!

Leave a Comment

You must be logged in to be able to post a comment.

Get the latest news and updates from Stockhouse on social media


Featured Company